3 providers are running promotional pricing right now. Two of them don't say when it ends. · Verified September 15, 2026
It is not a coverage decision your plan made, which is why appealing it usually goes nowhere.
The short answer. Insurance plans and pharmacy benefit managers pay claims against FDA-approved products, which are identified by an NDC — a National Drug Code. Compounded medication is made for an individual patient and has no NDC, so in most cases there is nothing for the claim system to pay against. This is not a coverage judgment about whether you need the drug. It's that the claim has no product number to attach to.
Appeals work when a plan has decided something isn't medically necessary, or wants you to try a cheaper option first. Those are judgments, and judgments can be argued with.
This isn't that. A compounded preparation isn't a product the plan has assessed and declined — it's outside the system the claim runs through. Which is why people who successfully appeal a Wegovy or Zepbound denial often find the same appeal goes nowhere on a compounded version of the same molecule.
This is where the answer changed, and where most published comparisons are now wrong. Branded cash prices fell hard in 2026 — the manufacturers started selling direct. If you were told a year ago that branded medication costs $1,000+ a month without insurance, that number is stale.
| Medication | Cash price | Note |
|---|---|---|
| Wegovy (pill) | $149/mo | FDA-approved |
| Wegovy (pen) | $349/mo | $199 first two months |
| Zepbound (vials) | $299/mo | $299-449 depending on dose |
Against that, compounded options currently start around $60–$99/month. Still cheaper — but the gap has narrowed from roughly ten-to-one to under two-to-one, and it no longer looks like the obvious decision it was in 2024.
See the current compounded prices, verified this week →
Compounded semaglutide and tirzepatide are not FDA-approved products. FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients. A compounded preparation is not a generic version of Wegovy, Ozempic, Zepbound or Mounjaro, and is not established as equivalent to them.
That distinction is also the answer to the insurance question — the absence of FDA approval is precisely why there's no NDC, and the absence of an NDC is why the claim has nothing to attach to. The two facts are the same fact.
That spread moves. 3 of these providers are running promotional pricing right now, and two of them will not say when it ends. We check every week. Want us to tell you when yours changes?
Your email and nothing else. Not your weight, your dose, or which page you were reading. We deliberately do not store that. No trackers, never sold.